Semi-supervised graph cut algorithm for drug repositioning by integrating drug, disease and genomic associations

Drug discovery is a cost expensive and time consuming process. Approved drugs have favorable or validated pharmacokinetic properties and toxicological profiles. Therefore repurposing approved drugs to new diseases can potentially avoid expensive costs associated with the early-stage testing. In this work, we propose to integrate drug-drug, disease-disease, gene-gene and drug-disease associations to reposition the approved drugs. Firstly, multiple sources of data are integrated into three layers: the chemical/phenotype layer, the gene/machanism layer and the treatment layer. Secondly, the drug-drug and disease-disease similarities in three layers are respectively computed and then combined together. Finally, based on the hypothesis that similar drugs may treat similar diseases, we model the drug repositioning problem as an optimal problem and propose a semi-supervised graph cut (SSGC) algorithm to solve the problem. The experimental results show that integrating multiple sources of data can achieve better performances than only considering single kind of data, and our method outperforms three representative approaches. Moreover, the predicted top-ranked repositioned relations have been reported in literature, illustrating the usefulness of our method in practice. The predicted results are available at https://github.com/wgs666/SSGC.git.

[1]  Jane S. Paulsen,et al.  Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. , 2008, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[2]  Livia Perfetto,et al.  MINT, the molecular interaction database: 2009 update , 2009, Nucleic Acids Res..

[3]  Nir Giladi,et al.  Olanzapine in Huntington's disease , 2002, Acta neurologica Scandinavica.

[4]  Ulrike von Luxburg,et al.  A tutorial on spectral clustering , 2007, Stat. Comput..

[5]  Francisco S. Roque,et al.  A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes , 2008, Proceedings of the National Academy of Sciences.

[6]  Zhiyong Lu,et al.  A survey of current trends in computational drug repositioning , 2016, Briefings Bioinform..

[7]  F. Iorio,et al.  Transcriptional data: a new gateway to drug repositioning? , 2013, Drug discovery today.

[8]  R. Roos,et al.  Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study , 1997, Journal of neurology, neurosurgery, and psychiatry.

[9]  Chuang Liu,et al.  Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..

[10]  Yoshihiro Yamanishi,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.

[11]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[12]  W. Koroshetz,et al.  Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. , 2006, Psychosomatics.

[13]  Xiang Zhang,et al.  Drug repositioning by integrating target information through a heterogeneous network model , 2014, Bioinform..

[14]  G. Vriend,et al.  A text-mining analysis of the human phenome , 2006, European Journal of Human Genetics.

[15]  R. Sharan,et al.  PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.

[16]  David Weininger,et al.  SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..

[17]  Yong Wang,et al.  Correction: Drug Repositioning by Kernel-Based Integration of Molecular Structure, Molecular Activity, and Phenotype Data , 2013, PLoS ONE.

[18]  Roded Sharan,et al.  Combining Drug and Gene Similarity Measures for Drug-Target Elucidation , 2011, J. Comput. Biol..

[19]  A. Chiang,et al.  Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses , 2009, Clinical pharmacology and therapeutics.

[20]  Zuping Zhang,et al.  Network-Based Inference Methods for Drug Repositioning , 2015, Comput. Math. Methods Medicine.

[21]  Jing Li,et al.  Drug Target Predictions Based on Heterogeneous Graph Inference , 2012, Pacific Symposium on Biocomputing.

[22]  R. Bonelli,et al.  Ziprasidone in Huntington’s Disease: The First Case Reports , 2003, Journal of psychopharmacology.

[23]  Cui Tao,et al.  Exploring the Pharmacogenomics Knowledge Base (PharmGKB) for Repositioning Breast Cancer Drugs by Leveraging Web Ontology Language (OWL) and Cheminformatics Approaches , 2013, Pacific Symposium on Biocomputing.

[24]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[25]  S. Scheindlin,et al.  Rare diseases, orphan drugs, and orphaned patients. , 2006, Molecular interventions.

[26]  G. Giaccone,et al.  Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). , 2003, European journal of cancer.

[27]  Zhiyong Lu,et al.  Pathway-based drug repositioning using causal inference , 2013, BMC Bioinformatics.

[28]  Joshua F. McMichael,et al.  DGIdb - Mining the druggable genome , 2013, Nature Methods.

[29]  A. Ardizzoni,et al.  Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. , 2007, Journal of the National Cancer Institute.

[30]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Bernhard Schölkopf,et al.  Learning with Local and Global Consistency , 2003, NIPS.